Proof-of-Concept Study of Neflamapimod

• Research type

  Research Study

• Full title

  A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer’s Disease

• IRAS ID

  242270

• Contact name

  Roger Bullock

• Contact email

  rogerbullock@stpancrasclinical.com

• Sponsor organisation

  EIP Pharma LLC

• Eudract number

  2017-004388-11

• Duration of Study in the UK

  1 years, 6 months, 0 days

• Research summary

  Alzheimer’s disease is a progressive neurodegenerative disorder characterized by deterioration of memory and other aspects of cognition, progressive impairment of activities of daily living, and a variety of behavioral disturbances.

  The purpose of this study is to replicate the results obtained from previous studies with neflamapimod. A new drug named, neflamapimod (VX-745) will be tested for the treatment of mild AD. More specifically, the aim of this study is to find out the level of improvement in:
  • Verbal learning and memory
  • Cognitive and functional performance
  • Chemical changes in spinal fluid

  Approximately 152 male and female patients, between 55 and 85 years of age, with a diagnosis of mild AD, will take part in this research study at different locations worldwide. The research study will involve eight visits to the clinic over 30 weeks and a Follow-up Visit about two weeks after the last dose of study drug.

• REC name

  London - Riverside Research Ethics Committee

• REC reference

  18/LO/0387

• Date of REC Opinion

  26 Apr 2018

• REC opinion

  Further Information Favourable Opinion